Celon Pharma S.A. with a poster session at ESMO 2017

Poster Design and development of potent E1 ubiquitin activating enzyme inhibitor, CPL-410-005, as novel anticancer therapy – Presented by the leader of the Oncology research team, Aleksandra Stańczak MD at this year’s largest cancer treatment conference. The European Society of Medical Oncology Meeting was held on 9-12 September.  It was participated by 24 thousand participants from 131Read more »

Celon Pharma S.A. receives a construction permit for its Research and Development Centre in Kazuń Nowy.

Celon Pharma S.A. received the final decision on the approval of the construction project and granting the Company a building permit for the construction of its Research and Development Centre located in Kazuń Nowy. The total cost of building and equipping the Research and Development Centre with specialised laboratory equipment (without taking into account theRead more »

Celon Pharma S.A. Finalised an agreement with Plexus Ventures

In line with the contractual provisions, Plexus Ventures will develop a strategy for development of drug candidates and will organise meetings with potential partners. If significant clinical progress is obtained and the parties agree on the development strategy for the drug(s), Plexus Ventures will take steps to obtain partners for the development or licensees, orRead more »

Celon Pharma S.A. received a positive assessment and funding recommendation from the National Centre for Research and Development (NCBiR) for 3 projects of developing innovative medicinal products

The applications where subject to a full, two-stage expert assessment and were selected from among a total of 23 submitted projects applying for co-funding from the InnoNeuroPharm programme. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:  Sector-specific programmes are very important tools for supporting research and development activity in the entire industry inRead more »

Aleksandra Stańczak at the opening of the Early Phase Trial Oncology Ward in Warsaw

On 29 June this year the first Early Phase Trial Oncology in Poland was opened in the Maria Skłodowska-Curie Institute of Oncology in Warsaw. During the scientific session, Aleksandra Stańczak, MD – leader of the Oncology Research group – presented the following project: Celonko – an innovative anti-FGFR therapy for patients with urinary bladder, lung andRead more »

Forbes’s Diamond award goes to Celon Pharma S.A.

Celon Pharma S.A. was awarded in the category of companies with revenues ranging from PLN 50 to 250 million and was placed 10th in the entire ranking in the Mazowieckie voivodship. Forbes Diamonds are awarded to the most dynamically developing companies in Poland. The award was accepted on behalf of the company by Iwona Giedronowicz,Read more »

The Industrial Development Agency conference participated by Celon Pharma S.A.

On 19 June this year, Maciej Wieczorek was invited by the Industrial Development Agency to participate in a meeting entitled: Quo vadis medicine. The pharmaceutical market and perspectives for its development. During the discussion panel attended by representatives of pharmaceutical companies, trade unions and VC funds, effective instruments for financing innovation in pharmacy and theRead more »